Background paper to the updated pneumococcal vaccination recommendation for older adults in Germany

The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50 years of age and older: A systematic review and meta-analysis

(2016) Hannah Kraicer-Melamed et al.   VACCINE

Efficacy of PPV23 in Preventing Pneumococcal Pneumonia in Adults at Increased Risk – A Systematic Review and Meta-Analysis

(2016) Julia Schiffner-Rohe et al.   PLoS One

Capsular Polysaccharide (CPS) Release by Serotype 3 Pneumococcal Strains Reduces the Protective Effect of Anti-Type 3 CPS Antibodies

(2015) Eun Hwa Choi et al.   Clinical and Vaccine Immunology

Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against Invasive Disease and Hospital-Treated Pneumonia Among People Aged ≥65 Years: A Retrospective Case-Control Study

(2015) Maya Leventer-Roberts et al.   CLINICAL INFECTIOUS DISEASES

Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia

(2015) Chamira Rodrigo et al.   EUROPEAN RESPIRATORY JOURNAL

Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults

(2015) Marc J.M. Bonten et al.   NEW ENGLAND JOURNAL OF MEDICINE

The 23-valent pneumococcal polysaccharide vaccine is effective in elderly adults over 75 years old—Taiwan's PPV vaccination program

(2015) Ying-Huang Tsai et al.   VACCINE

Effects of Infant Pneumococcal Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany

(2015) Mark van der Linden et al.   PLoS One

Changes in Pneumococcal Serotypes and Antimicrobial Resistance after Introduction of the 13-Valent Conjugate Vaccine in the United States

(2014) Sandra S. Richter et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine Against Community-Acquired Pneumonia in the General Population Aged >=60 Years: 3 Years of Follow-up in the CAPAMIS Study

(2014) O. Ochoa-Gondar et al.   CLINICAL INFECTIOUS DISEASES

Impact of 13-Valent Pneumococcal Conjugate Vaccination in Invasive Pneumococcal Disease Incidence and Mortality

(2014) Zitta Barrella Harboe et al.   CLINICAL INFECTIOUS DISEASES

The aetiology and antibiotic management of community-acquired pneumonia in adults in Europe: a literature review

(2014) A. Torres et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Effectiveness of 23-valent pneumococcal polysaccharide vaccine in adults aged 60 years and over in the Region of Madrid, Spain, 2008–2011

(2014) M A Gutiérrez Rodríguez et al.   Eurosurveillance

CpG Drives Human Transitional B Cells to Terminal Differentiation and Production of Natural Antibodies

(2014) F. Capolunghi et al.   JOURNAL OF IMMUNOLOGY

Human Memory B Lymphocyte Subsets Fulfill Distinct Roles in the Anti-Polysaccharide and Anti-Protein Immune Response

(2014) L. Moens et al.   JOURNAL OF IMMUNOLOGY

Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study

(2014) Nick J Andrews et al.   LANCET INFECTIOUS DISEASES

Effect of Pneumococcal Conjugate Vaccination in Uruguay, a Middle-Income Country

(2014) Gabriela García Gabarrot et al.   PLoS One

Incidence and etiology of community-acquired pneumonia in the elderly in a prospective population-based study

(2014) Arto A. Palmu et al.   SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES

Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England

(2014) Albert Jan van Hoek et al.   VACCINE

Cost-effectiveness of childhood rotavirus vaccination in Germany

(2014) Pamela Aidelsburger et al.   VACCINE

Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine–naïve adults 60–64 years of age

(2014) Richard N. Greenberg et al.   VACCINE

The effectiveness of the polysaccharide pneumococcal vaccine for the prevention of hospitalizations due to Streptococcus pneumoniae community-acquired pneumonia in the elderly differs between the sexes: Results from the Community-Acquired Pneumonia Organization (CAPO) international cohort study

(2014) Timothy L. Wiemken et al.   VACCINE

Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults

(2014) Christine Juergens et al.   Human Vaccines & Immunotherapeutics

Impfstatus von Erwachsenen in Deutschland

(2013) C. Poethko-Müller et al.   Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz

Preserved antibody levels and loss of memory B cells against pneumococcus and tetanus after splenectomy: Tailoring better vaccination strategies

(2013) M. Manuela Rosado et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Discovery ofStreptococcus pneumoniaeSerotype 6 Variants with Glycosyltransferases Synthesizing Two Differing Repeating Units

(2013) Melissa B. Oliver et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Systematic Review and Meta-Analysis of a Urine-Based Pneumococcal Antigen Test for Diagnosis of Community-Acquired Pneumonia Caused by Streptococcus pneumoniae

(2013) A. Sinclair et al.   JOURNAL OF CLINICAL MICROBIOLOGY

The Immune Response to Pneumococcal Polysaccharides 14 and 23F Among Elderly Individuals Consists Predominantly of Switched Memory B Cells

(2013) David J. Leggat et al.   JOURNAL OF INFECTIOUS DISEASES

Serotype Distribution in Non-Bacteremic Pneumococcal Pneumonia: Association with Disease Severity and Implications for Pneumococcal Conjugate Vaccines

(2013) Thomas Benfield et al.   PLoS One

Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older

(2013) Lisa A. Jackson et al.   VACCINE

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

(2013) Lisa A. Jackson et al.   VACCINE

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults

(2013) Lisa A. Jackson et al.   VACCINE

Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995–2011

(2013) Wallis Rudnick et al.   VACCINE

Sustained functional serotype-specific antibody after primary and secondary vaccinations with a pneumococcal polysaccharide vaccine in elderly patients with chronic lung disease

(2013) Nobuharu Ohshima et al.   VACCINE

Validation of an Immunodiagnostic Assay for Detection of 13 Streptococcus pneumoniae Serotype-Specific Polysaccharides in Human Urine

(2012) Michael W. Pride et al.   Clinical and Vaccine Immunology

Randomized, Controlled Trial of a 13-Valent Pneumococcal Conjugate Vaccine Administered Concomitantly with an Influenza Vaccine in Healthy Adults

(2012) Robert W. Frenck et al.   Clinical and Vaccine Immunology

Long-term Comparative Immunogenicity of Protein Conjugate and Free Polysaccharide Pneumococcal Vaccines in Chronic Obstructive Pulmonary Disease

(2012) Mark T. Dransfield et al.   CLINICAL INFECTIOUS DISEASES

The role of Streptococcus pneumoniae in community-acquired pneumonia among adults in Europe: a meta-analysis

(2012) M. H. Rozenbaum et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

The fundamental link between pneumococcal carriage and disease

(2012) Birgit Simell et al.   Expert Review of Vaccines

Phenotypic Analysis of Pneumococcal Polysaccharide-Specific B Cells

(2012) N. Khaskhely et al.   JOURNAL OF IMMUNOLOGY

Pneumococcal Conjugate and Plain Polysaccharide Vaccines Have Divergent Effects on Antigen-Specific B Cells

(2012) Elizabeth A. Clutterbuck et al.   JOURNAL OF INFECTIOUS DISEASES

Mathematical Modelling Long-Term Effects of Replacing Prevnar7 with Prevnar13 on Invasive Pneumococcal Diseases in England and Wales

(2012) Yoon Hong Choi et al.   PLoS One

Effect of Serotype on Focus and Mortality of Invasive Pneumococcal Disease: Coverage of Different Vaccines and Insight into Non-Vaccine Serotypes

(2012) Albert Jan van Hoek et al.   PLoS One

Clinical effectiveness of pneumococcal polysaccharide vaccine in men: California Men's Health Study

(2012) Rulin C. Hechter et al.   VACCINE

Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales

(2012) Nick J. Andrews et al.   VACCINE

Community-acquired pneumonia in younger patients is an entity on its own

(2011) Benjamin Klapdor et al.   EUROPEAN RESPIRATORY JOURNAL

Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults

(2011) Daniel M. Musher et al.   Human vaccines & immunotherapeutics

GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables

(2011) Gordon Guyatt et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Serotype replacement in disease after pneumococcal vaccination

(2011) Daniel M Weinberger et al.   LANCET

Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55–74 years living in Alaska: No evidence of hyporesponsiveness☆☆☆

(2011) Laura L. Hammitt et al.   VACCINE

A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years

(2011) T.F. Schwarz et al.   VACCINE

Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease

(2010) Alessia Melegaro et al.   BMC INFECTIOUS DISEASES

Safety and Antibody Response, Including Antibody Persistence for 5 Years, after Primary Vaccination or Revaccination with Pneumococcal Polysaccharide Vaccine in Middle‐Aged and Older Adults

(2010) Daniel M. Musher et al.   JOURNAL OF INFECTIOUS DISEASES

Revaccination with a 23‐Valent Pneumococcal Polysaccharide Vaccine Induces Elevated and Persistent Functional Antibody Responses in Adults Aged ⩾65 Years

(2010) Susan B. Manoff et al.   JOURNAL OF INFECTIOUS DISEASES

Circulating pneumococcal specific plasma and memory B cells in the elderly two years after pneumococcal conjugate versus polysaccharide vaccination

(2010) Helen E. Baxendale et al.   VACCINE

The early kinetics of circulating pneumococcal-specific memory B cells following pneumococcal conjugate and plain polysaccharide vaccines in the elderly

(2010) Helen E. Baxendale et al.   VACCINE

The thymus-independent immunity conferred by a pneumococcal polysaccharide is mediated by long-lived plasma cells

(2009) M. Taillardet et al.   BLOOD

The controversy over the efficacy of pneumococcal vaccine

(2009) R. Andrews et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Efficacy of pneumococcal polysaccharide vaccine

(2009) P. Scott et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Efficacy of pneumococcal vaccination in adults: a meta-analysis

(2009) A. Huss et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Immune Response in Infants to the Heptavalent Pneumococcal Conjugate Vaccine against Vaccine-Related Serotypes 6A and 19A

(2009) H. Lee et al.   Clinical and Vaccine Immunology

Sustained Reductions in Invasive Pneumococcal Disease in the Era of Conjugate Vaccine

(2009) Tamara Pilishvili et al.   JOURNAL OF INFECTIOUS DISEASES

Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: A matched case–control study

(2009) Angel Vila-Corcoles et al.   VACCINE

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE